11/15
09:34 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
09:28 am
spro
Rating for SPRO
Medium
Report
Rating for SPRO
10/3
08:18 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.